Innovent Biologics (suzhou) Co. Ltd.

This phase II trial is testing whether a new investigational drug called IBI3003, when combined with an existing anti-CD38 antibody (daratumumab), can improve outcomes for people with multiple myeloma. The study includes patients with relapsed or refractory disease, as well as ne…

This early-stage trial is testing an investigational drug called IBI3040, given as an injection under the skin. The study will first give a single dose to healthy adults to check safety, then multiple doses to overweight or obese adults to see how the drug behaves and whether it …

This trial is testing whether an experimental biologic called IBI3027 works as well as the approved drug dupilumab for people with moderate-to-severe atopic dermatitis (eczema). About 520 adults will be randomly assigned to receive either IBI3027 or dupilumab as a subcutaneous in…

This Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their do…

This study tests a new drug combination (IBI3005) in about 282 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. Participants will be closely monitored for side effects a…

This early-stage study tests a single injection of a new drug, IBI3016, in 30 Chinese adults with mild to moderate hypertension who are not currently on blood pressure medication. The main goal is to check safety and how the drug moves through the body, with a secondary look at i…

This study tests a drug called IBI363 given before surgery for people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the drug helps shrink or eliminate the tumor before the operation. About 10 participants will receive IBI363, and resea…

This study tests an experimental drug called IBI3016 in people with mild to moderate high blood pressure. Participants receive either the drug or a placebo as an injection every 3 or 6 months for up to 2 years. The goal is to see if the drug safely lowers blood pressure better th…

This study looks at how well the drug taletrectinib works in people with advanced ROS1-positive non-small cell lung cancer whose cancer has gotten worse after treatment with entrectinib. Researchers will follow 50 patients in real-world clinics to see if the drug shrinks tumors a…

This early-stage trial is testing an experimental drug called IBI3033 in 16 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants will receive either IBI3033 or a placebo injection over…